vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and Piedmont Realty Trust, Inc. (PDM). Click either name above to swap in a different company.
Guardant Health, Inc. is the larger business by last-quarter revenue ($281.3M vs $143.3M, roughly 2.0× Piedmont Realty Trust, Inc.). Piedmont Realty Trust, Inc. runs the higher net margin — -31.4% vs -45.7%, a 14.3% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 0.4%). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs 0.0%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
Piedmont Realty Trust, Inc. is a publicly traded real estate investment trust (REIT) that owns, operates, and invests in high-quality office properties primarily located in high-growth metropolitan areas across the United States. It serves corporate tenants across multiple industry sectors including technology, professional services, and healthcare, and pursues stable long-term returns for stakeholders via strategic property management and portfolio optimization.
GH vs PDM — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $143.3M |
| Net Profit | $-128.5M | $-45.0M |
| Gross Margin | 64.6% | — |
| Operating Margin | -43.0% | — |
| Net Margin | -45.7% | -31.4% |
| Revenue YoY | 39.4% | 0.4% |
| Net Profit YoY | -15.8% | -27.9% |
| EPS (diluted) | $-1.01 | $-0.10 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $143.3M | ||
| Q4 25 | $281.3M | $142.9M | ||
| Q3 25 | $265.2M | $139.2M | ||
| Q2 25 | $232.1M | $140.3M | ||
| Q1 25 | $203.5M | $142.7M | ||
| Q4 24 | $201.8M | $143.2M | ||
| Q3 24 | $191.5M | $139.3M | ||
| Q2 24 | $177.2M | $143.3M |
| Q1 26 | — | $-45.0M | ||
| Q4 25 | $-128.5M | $-43.2M | ||
| Q3 25 | $-92.7M | $-13.5M | ||
| Q2 25 | $-99.9M | $-16.8M | ||
| Q1 25 | $-95.2M | $-10.1M | ||
| Q4 24 | $-111.0M | $-30.0M | ||
| Q3 24 | $-107.8M | $-11.5M | ||
| Q2 24 | $-102.6M | $-9.8M |
| Q1 26 | — | — | ||
| Q4 25 | 64.6% | — | ||
| Q3 25 | 64.7% | — | ||
| Q2 25 | 65.0% | — | ||
| Q1 25 | 63.3% | — | ||
| Q4 24 | 61.6% | — | ||
| Q3 24 | 61.1% | — | ||
| Q2 24 | 59.1% | — |
| Q1 26 | — | — | ||
| Q4 25 | -43.0% | — | ||
| Q3 25 | -37.3% | — | ||
| Q2 25 | -45.9% | — | ||
| Q1 25 | -54.6% | — | ||
| Q4 24 | -62.4% | — | ||
| Q3 24 | -61.3% | — | ||
| Q2 24 | -56.8% | — |
| Q1 26 | — | -31.4% | ||
| Q4 25 | -45.7% | -30.3% | ||
| Q3 25 | -35.0% | -9.7% | ||
| Q2 25 | -43.0% | -12.0% | ||
| Q1 25 | -46.8% | -7.1% | ||
| Q4 24 | -55.0% | -20.9% | ||
| Q3 24 | -56.3% | -8.3% | ||
| Q2 24 | -57.9% | -6.8% |
| Q1 26 | — | $-0.10 | ||
| Q4 25 | $-1.01 | $-0.34 | ||
| Q3 25 | $-0.74 | $-0.11 | ||
| Q2 25 | $-0.80 | $-0.14 | ||
| Q1 25 | $-0.77 | $-0.08 | ||
| Q4 24 | $-0.90 | $-0.25 | ||
| Q3 24 | $-0.88 | $-0.09 | ||
| Q2 24 | $-0.84 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | $2.3M |
| Total DebtLower is stronger | $1.5B | — |
| Stockholders' EquityBook value | $-99.3M | $1.5B |
| Total Assets | $2.0B | $4.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $2.3M | ||
| Q4 25 | $378.2M | $731.0K | ||
| Q3 25 | $580.0M | $3.0M | ||
| Q2 25 | $629.1M | $3.3M | ||
| Q1 25 | $698.6M | $2.9M | ||
| Q4 24 | $525.5M | $109.6M | ||
| Q3 24 | $585.0M | $133.6M | ||
| Q2 24 | $933.7M | $138.5M |
| Q1 26 | — | — | ||
| Q4 25 | $1.5B | $2.2B | ||
| Q3 25 | $1.1B | $2.2B | ||
| Q2 25 | $1.1B | $2.2B | ||
| Q1 25 | $1.1B | $2.2B | ||
| Q4 24 | $1.1B | $2.2B | ||
| Q3 24 | — | $2.2B | ||
| Q2 24 | — | $2.2B |
| Q1 26 | — | $1.5B | ||
| Q4 25 | $-99.3M | $1.5B | ||
| Q3 25 | $-354.5M | $1.5B | ||
| Q2 25 | $-305.5M | $1.5B | ||
| Q1 25 | $-250.8M | $1.6B | ||
| Q4 24 | $-139.6M | $1.6B | ||
| Q3 24 | $-60.1M | $1.6B | ||
| Q2 24 | $-1.6M | $1.7B |
| Q1 26 | — | $4.0B | ||
| Q4 25 | $2.0B | $4.0B | ||
| Q3 25 | $1.3B | $4.0B | ||
| Q2 25 | $1.3B | $4.0B | ||
| Q1 25 | $1.3B | $4.0B | ||
| Q4 24 | $1.5B | $4.1B | ||
| Q3 24 | $1.5B | $4.1B | ||
| Q2 24 | $1.6B | $4.2B |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.49× | ||
| Q3 25 | — | 1.43× | ||
| Q2 25 | — | 1.41× | ||
| Q1 25 | — | 1.40× | ||
| Q4 24 | — | 1.40× | ||
| Q3 24 | — | 1.36× | ||
| Q2 24 | — | 1.34× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | — |
| Free Cash FlowOCF − Capex | $-54.2M | — |
| FCF MarginFCF / Revenue | -19.3% | — |
| Capex IntensityCapex / Revenue | 9.9% | 110.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-26.4M | $140.6M | ||
| Q3 25 | $-35.4M | $35.8M | ||
| Q2 25 | $-60.3M | $50.1M | ||
| Q1 25 | $-62.7M | $3.7M | ||
| Q4 24 | $-64.5M | $198.1M | ||
| Q3 24 | $-51.1M | $42.9M | ||
| Q2 24 | $-94.0M | $66.8M |
| Q1 26 | — | — | ||
| Q4 25 | $-54.2M | — | ||
| Q3 25 | $-45.8M | — | ||
| Q2 25 | $-65.9M | — | ||
| Q1 25 | $-67.1M | — | ||
| Q4 24 | $-83.4M | — | ||
| Q3 24 | $-55.3M | — | ||
| Q2 24 | $-99.1M | — |
| Q1 26 | — | — | ||
| Q4 25 | -19.3% | — | ||
| Q3 25 | -17.3% | — | ||
| Q2 25 | -28.4% | — | ||
| Q1 25 | -33.0% | — | ||
| Q4 24 | -41.3% | — | ||
| Q3 24 | -28.9% | — | ||
| Q2 24 | -55.9% | — |
| Q1 26 | — | 110.3% | ||
| Q4 25 | 9.9% | — | ||
| Q3 25 | 3.9% | — | ||
| Q2 25 | 2.4% | — | ||
| Q1 25 | 2.2% | — | ||
| Q4 24 | 9.4% | — | ||
| Q3 24 | 2.2% | — | ||
| Q2 24 | 2.9% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
PDM
Segment breakdown not available.
